Ukunyanga i-HIV kunye no-Odefsey

Ukuhlanganiswa okuphucukisiwe Izidakamizwa zinikela ngeempembelelo ezimbalwa

Ukwahlula

U-Odefsey ungumntu oyedwa-tablet, i-dose egxininisiweyo isilwanyana esisetyenziswe kunyango lwe-HIV, elinezixhobo ezintathu ezichasene ne- antiretroviral :

U-Odefsey uyisisombululo sesibini sokudibanisa ukusebenzisa i-TAF, inguqu "ephuculweyo" ye-tenofovir disoproxil fumarate (i-TDF) efunyenwe kwiziyobisi iTruvada neAtripla .

Ngaloo ndlela, kunokuqwalaselwa ukuphuculwa kwi-Complera, ukufakelwa kwethebhulethi enye kunye ne-rilpivirine + emtricitabine + TDF.

I-TAF ithathwa njengophezulu kwi-TDF njengoko iyakwazi ukuhambisa isilwanyana esisebenzayo ngokuthe ngempumelelo kwiiseli kunye nakwizinga elincinci kakhulu-kuthetha ukuba kukho ukuqokelelwa okuncane kweziyobisi kwigazi kunye nethuba elincinci lokuvelisa iziyobisi ezinxulumene neziyobisi.

(Nangona ubungozi be-TDF-inxulumene neengxaki zesifo seengxaki kubonwa phantsi kumazwe athuthukile, loo mngcipheko ubonakala ukunyuka kakhulu kumazwe asathuthuka apho kukho iziganeko ezinkulu zentsholongwane ekhoyo ngaphambili.)

Inkcazo yokwelapha

U-Odefsey uvunyiwe yi-US Food and Drug Administration ngoMatshi 1, 2016 ukuze kusetshenziswe kubantu abadala kunye nabantwana abangaphezu kweminyaka eyi-12 abangakaze bafumane unyango lwe-HIV , abanomthamo we- viral of 100,000 / m okanye ngaphantsi. 77 iipounds (35kg) okanye ngaphezulu.

I-Odefsey ingasetyenziselwa ukutshintshwa kwonyango lwangoku (njengalezo kwi-Complera) ukuba isigulane sinomthwalo we-viral (<50 cells / mL) ubuncinane ubuncinane kwiinyanga ezintandathu, ayikho imbali yokungaphumeleli kwonyango, kwaye ayikwazi ukuchasana nawaphi na amacandelo eziyobisi e-Odefsey.

UkuQulunqa

I-Odefsey yipilisi eboyiweyo, i-oblong, enefilimu, ene-25mg ye-rilpivirine, i-200mg ye-emtricitabine kunye ne-25 mg ye-TAF.

I-GSI "ngapha nangapha kunye ne" 255 "kwenye.

Isistim

Ithebhulethi nganye imihla ngemihla ithathwa ngokutya. U-Odefsey akufanele athathwe naliphi na isicatshulwa se-antiretroviral esisetyenziselwa ukuphatha i-HIV.

Imiphumela

Inani lezonyango ezichaphazelekayo ziye zaphawulwa kwizigulana zecilini zecilisi ezithatha i-rilpivirine kunye / okanye i-emtricitabine + i-TAF, eyona nto ibhelele kuyo:

Imiphumo emibi yayidlulileyo, kwaye izigulana ezimbalwa ziyeka ngenxa yokunyamezela unyango.

Ukungqinelana

U-Odefsey akufanele athathwe ngamachiza alandelayo okanye izongezelo:

Njalo uxelele ugqirha wakho nasiphi na isilwanyana okanye isongezelelo, esimiselweyo okanye esingasimiselweyo, ukuba ungathatha ngaphambi kokuba uqalise nayiphi na unyango lwe-antiretroviral.

Ezinye izinto

I-Odefsey ayikhuthazwa izigulane ezinokukhubazeka kweengtso (ichazwe njengento yokucwangciswa kokudalwa kwemveli engaphantsi kwe-30mL ngomzuzu).

Nceda ugqirha ugqirha ukuba ngaba ukhona okanye uphathwa ngayo nayiphi na ingxaki yengqondo yomnye ugqirha.

U-Odefsey akacebisikanga kwizigulane ezinobungozi besibindi okanye abo abane- HBV yokusuleleka kwintsholongwane engapheliyo njengokuba kunokunyusa kakhulu ingxaki yesibindi. Kucetyiswa ukuba abantu abane-HIV bahlolwe i-HBV ngaphambi kokumisela u-Odefsey. Nceda ugqirha ugqirha wakho ukuba unayo nayiphi na ingxaki yesibindi kunye / okanye imbali ye-hepatitis.

I-rilpivirine yecandelo le-Odefsy lingabangela ukuphendulwa kwe-hypersensitivity kwinani elincinci lezigulane, ngokuphindaphindiwe ngendlela yokuqhaqhazela, ukuvuvuka kweso ("iso elincinci"), ukuvuvukala ubuso, umkhuhlane okanye ezinye izimpendulo.

Ngokuqhelekileyo, iimpendulo ze-hypersensitivity zikhona emva kweeveki ezi-1-6 emva kokuqala kweyeza. Mcebisa ugqirha wakho ngoko nangoko naziphi na iimpawu ezibonakalayo. Kwiimeko ezinzima, unyango luya kufuneka luyeke.

Imithombo:

Reuters. "I-BRIEF - I-Scientific Sciences eGiliyadi ithi i-US FDA iyavuma i-Odefsey." Kukhutshwa ngoMatshi 1, 2015.

KwiSayensi zeGiliyadi. "I- Odefsey - eziphambili zeNgcaciso. Foster City, California; kufike ngoMatshi 18, 2016.